SCHEMBL5499896

SCHEMBL5499896

CCC1(C)C(=O)Nc2ccc(Br)cc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
TP53 P04637 2/20 0.46
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
AKR1B1 P15121 1/20 0.44
GAA P10253 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
PKM P14618 1/20 0.44
MAPT P10636 3/20 0.43
KDM4E B2RXH2 1/20 0.43
USP2 O75604 2/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MGAM O43451 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
ALPL P05186 1/20 0.43
HSP90AA1 P07900 1/20 0.43
ALPI P09923 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5497405 0.93 MAPT (0.48) LMNATP53ALDH1A1MEN1KMT2A
SCHEMBL16566160 0.87 LMNA (0.46) LMNATP53ALDH1A1MEN1KMT2A
SCHEMBL31220002 0.87 MEN1 (0.44) LMNATP53ALDH1A1MEN1KMT2A
SCHEMBL16566099 0.83 MEN1 (0.48) LMNATP53ALDH1A1MEN1KMT2A
SCHEMBL24740168 0.81 CYP1A2 (0.51) LMNATP53ALDH1A1MEN1KMT2A
SCHEMBL12859308 0.81 CYP1A2 (0.51) LMNATP53ALDH1A1MEN1KMT2A
SCHEMBL1696201 0.81 PGR (0.55) LMNATP53ALDH1A1MEN1KMT2A
SCHEMBL19410670 0.80 LMNA (0.46) LMNATP53ALDH1A1MEN1KMT2A
SCHEMBL19410676 0.80 PGR (0.62) TP53ALDH1A1MAPTKDM4EADAMTS5
SCHEMBL19410687 0.80 PIK3CD (0.51) LMNATP53ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024064316-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 INHIBITORS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-03-28 WO disclosed
EP-3041821-B1 BICYLIC COMPOUNDS AS MODULATORS OF RORGAMMA BOEHRINGER INGELHEIM INT (DE) 2018-05-30 EP disclosed
US-9745267-B2 Compounds as modulators of RORC BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-08-29 US disclosed
US-9745267-B2 Compounds as modulators of RORC BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-08-29 US disclosed
US-20160251310-A1 COMPOUNDS AS MODULATORS OF RORC BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-09-01 US disclosed
US-20160251310-A1 COMPOUNDS AS MODULATORS OF RORC BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-09-01 US disclosed
WO-2015035032-A1 BICYLIC COMPOUNDS AS MODULATORS OF RORGAMMA BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-03-12 WO disclosed
EP-1778222-A1 PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF Wyeth (US) 2007-05-02 EP disclosed
WO-2006023107-A1 PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF WYETH (US) 2006-03-02 WO disclosed
US-20060030615-A1 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251310-A1 COMPOUNDS AS MODULATORS OF RORC RORC, RORB, RORA LMNA 3147/4885TP53 4512/4885ALDH1A1 131/4885
US-20060030615-A1 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof PGR, PGRMC2, PGRMC1 LMNA 4489/4885TP53 3081/4885ALDH1A1 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.